Company: AZN
Filing Date: 2025-06-26
Form Type: 11-K
Source: 0001683168-25-004771
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-06-26
Form: 11-K
Chunk 7
---
 are the employer matching
contributions.

Investments
are reported at fair value (except for the fully benefit-responsive investment contracts, which are reported at contract value). Fair
value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. The Plan’s Investment Committee determines the Plan’s valuation policies utilizing information provided by the
investment advisers, custodians and insurance companies. See note 4 for discussion of fair value measurements.

| 8 |

<div align='center'>ASTRAZENECA SAVINGS AND SECURITY PLAN

Notes to Financial Statements

December 31, 2024 and 2023

_______________</div>

| 2. | Significant Accounting Policies, continued: |

Investment Valuation and Income Recognition, continued:

Purchases
and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are record on
the ex-dividend date. Net appreciation includes the Plan’s gains and losses on investments bought and sold as well as held during the
year.

Notes Receivable from Participants:

Notes receivable
from participants (“loans”) are measured at their unpaid principal balance plus any accrued but unpaid interest. Defaulted participant
loans are reclassified as benefits paid based upon the terms of the Plan document.

Payment of Benefits:

Benefit payments are recorded when
paid.

The preparation
of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts
of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities. Actual results could differ from those
estimates.

| 3. | Fully                                    
 Benefit-Responsive Investment Contracts: |

The
Plan invests in a portfolio of fully benefit-responsive guaranteed investment contracts (“GICs”) issued by insurance companies
that is required to be reported at contract value. Invesco Advisers, Inc. serves as the investment manager for the portfolio since December
15, 2022, with oversight from the AstraZeneca Investment Committee. The portfolio is credited with interest on the GICs and debited for
participant withdrawals.

Participants
may direct the withdrawal or transfer of all or a portion of their investment. Participants cannot transfer their balance to a competing
investment option without the amount of such transfer first being directed to one of the Plan’s other investment options and held
thereunder for at least 90 days.

The
Plan holds two